- Active, not recruiting
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
The purpose of this study is to expand upon the safety data for carfilzomib by providing expanded access to patients with relapsed and refractory multiple myeloma who are unable to enroll in any other ongoing carfilzomib trial.
Sponsor
Amgen
Collaborator
Multiple Myeloma Research Foundation
ClinicalTrials.gov Identifier: NCT01410500
Official Title: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
First Posted : August 5, 2011
Click here to see details on ClinicalTrials.gov
Drug: Carfilzomib
Location
United States